Cyclic 11β-HSD1 Inhibitors for Selective Metabolic Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions related to 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity, such as obesity, metabolic syndrome, and glucocorticoid-related disorders, lack effective inhibitors that can specifically target and inhibit 11β-HSD1 activity without systemic side effects.
Innovation Solution
Development of novel compounds represented by Formula Im1 and its pharmaceutically acceptable salts, enantiomers, or diastereomers, which act as effective inhibitors of 11β-HSD1, administered in pharmaceutical compositions to specifically target and inhibit 11β-HSD1 activity in mammals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for 11β-HSD1-related conditions, then systemic side effects occur, but effective inhibition of 11β-HSD1 activity is not achieved
Solution Approach 1:
The patent develops compounds that selectively inhibit 11β-HSD1 in specific tissues (adipose tissue, liver, eye) while sparing other organs. The compounds achieve tissue-specific inhibition through selective binding to the 11β-HSD1 enzyme isoform, which is differentially expressed in various tissues, thereby providing local therapeutic effects without systemic side effects
Solution Approach 2:
The patent modifies molecular parameters of inhibitor compounds to optimize their selectivity for 11β-HSD1 over other steroid dehydrogenases. By adjusting structural parameters such as stereochemistry, functional groups, and molecular geometry, the compounds achieve enhanced specificity for 11β-HSD1, enabling effective inhibition with reduced off-target effects
2Reliability
If 11β-HSD1 activity is inhibited to treat obesity and metabolic syndrome, then local glucocorticoid concentrations are reduced, but achieving specific targeting without affecting other steroid pathways is challenging
Solution Approach 1:
The patent divides the molecular design into distinct functional segments: a steroid-like core structure for enzyme binding, specific substituent groups for selectivity, and pharmacophore elements for 11β-HSD1 recognition. This segmented approach allows systematic optimization of each component to achieve high selectivity while managing molecular complexity
Solution Approach 2:
The patent employs asymmetric molecular structures with specific stereochemical configurations that match the chiral binding pocket of 11β-HSD1. The asymmetric design enables selective interaction with 11β-HSD1's active site while avoiding other steroid dehydrogenases, achieving high selectivity through stereospecific binding
Data Source
AI summary
This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, lo1, lo2, lo5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.